CoChat
Sign Up
Cited by 38Nanoparticle-Based Drug DeliveryPharmacology and Nanomedicine ResearchDendrimers and Hyperbranched Polymers

Nanotechnology-based drug delivery for breast cancer treatment: Current applications and future directions

Open access
Samad, Md Abdus, Ahmad, Iftikhar, Zughaibi, Torki A., Suhail, Mohd, Zaidi, Syed Kashif, Al-Abbasi, Fahad A., Tabrez, Shams·2025·European Journal of Medicinal Chemistry Reports
DOI 10.1016/j.ejmcr.2025.100268
Open this paper in CoChat — free account

Abstract

Breast cancer (BC) is one of the most prevalent cancers in women worldwide. Limited specificity, systemic toxicity, risk of recurrence, and drug resistance are some of the drawbacks of traditional BC treatment approaches. Therefore, it is crucial to develop more effective, safe, and customized management plans for BC. The application of nanoparticle-based systems, such as liposomes, nanostructured lipid carriers, polymeric micelles, polymeric nanoparticles, dendrimers, and hybrid nanoparticles, has drawn significant interest in BC treatment. Nanomedicine can enhance the efficacy of drugs through active targeting, better tissue penetration, and more efficient tumor suppression via improved retention and permeability. Additionally, gene delivery using hybrid and theranostic nanomedicine has also been explored in BC treatment. Numerous nanomedicines have been used clinically for the treatment of breast cancer, some of which have already received U.S. Food and Drug Administration (USFDA) approval. Here, we focus on nanotechnology-based therapeutic approaches for BC treatment and highlighted their enhanced efficacy and reduced side effects. In addition, we have also explored on the possible utilization of Artificial Intelligence (AI) nanomedicine and bioinspired nanocarriers for BC treatment, which could pave the way for more precise, effective, and personalized therapies by improving nanoparticle design, optimizing drug delivery systems, and leveraging big data analytics.

Integrity signals

Registry

Crossref · 10.1016/j.ejmcr.2025.100268

Cites

336 of 336 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The route of administration remains a practical limitation, as intratumoral delivery may not be feasible for all anatomical sites, whereas systemic administration raises concerns regarding off-target accumulation and toxicity.

    “The route of administration also remains a practical limitation, as intratumoral delivery may not be feasible for all anatomical sites, whereas systemic administration raises concerns regarding off-target accumulation and toxicity [25,97].”

    From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [97]

  • Many preclinical studies rely on passive targeting through the enhanced permeability and retention (EPR) effect, which is highly variable and generally less pronounced in human tumors than in experimental models.

    “Many preclinical studies rely on passive targeting through the enhanced permeability and retention (EPR) effect, which is highly variable and generally less pronounced in human tumors than in experimental models [5,97].”

    From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [97]

  • These early systems established the proof-of-concept that nanomaterials could enhance radiation-induced damage, but also highlighted limitations related to tumor hypoxia, antioxidant defenses, heterogeneous intratumoral distribution, and variable nanoparticle accumulation.

    “These systems established the proof-of-concept that nanomaterials could enhance radiation-induced damage, but they also highlighted important limitations related to tumor hypoxia, antioxidant defenses, heterogeneous intratumoral distribution, and variable nanoparticle accumulation [11,12,25,95,97].”

    From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [97]

  • Clinical development of combinatorial nanoplatforms is challenged by issues related to reproducibility, manufacturing consistency, regulatory approval, scalability, and long-term safety.

    “Although these combinatorial systems often demonstrate enhanced efficacy experimentally, their clinical development is challenged by issues related to reproducibility, manufacturing consistency, regulatory approval, scalability, and long-term safety [25,96,97].”

    From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [97]

Cites

Flagged first, then by citations

7 of the 343 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Samad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S.
Affiliations
King Abdulaziz University (SA)
Corresponding author
Tabrez, Shams
ORCID
Venue
European Journal of Medicinal Chemistry Reports
Publisher
Elsevier BV
Published
2025-08
Volume
14
Pages
100268
ISSN
2772-4174 (ISSN-L)
DOI
10.1016/j.ejmcr.2025.100268
OpenAlex
W4409392096
Cited by
35
References
343
Citations by year
2026: 21 · 2025: 14
FWCI
7.40
Type
journal article
Language
en
Open access
Licence
Locations
  • European Journal of Medicinal Chemistry Reports (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • King Fahad Medical City
  • King Abdulaziz University
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
Keywords
breast cancer, nanomedicine, drug delivery systems, liposomes, nanostructured lipid carriers, polymeric micelles, polymeric nanoparticles, dendrimers, hybrid nanostructures, nanotheranostics, gene delivery, targeted drug delivery, drug resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review